Brokerages Set Nyxoah SA (NASDAQ:NYXH) PT at $11.67

Nyxoah SA (NASDAQ:NYXH) has received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $11.6667.

Several equities research analysts have weighed in on NYXH shares. Stifel Nicolaus lowered their target price on Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Cantor Fitzgerald upgraded shares of Nyxoah to a “strong-buy” rating in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and set a $9.00 target price (down from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th.

Institutional Investors Weigh In On Nyxoah

A number of large investors have recently modified their holdings of the business. Raymond James Financial Inc. lifted its stake in shares of Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares during the period. Bank of America Corp DE increased its holdings in Nyxoah by 72.4% in the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after acquiring an additional 3,303 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Nyxoah in the third quarter valued at about $98,000. Deutsche Bank AG boosted its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC purchased a new stake in shares of Nyxoah in the 2nd quarter valued at $374,000.

Nyxoah Price Performance

NYXH stock opened at $3.74 on Thursday. Nyxoah has a 1 year low of $3.65 and a 1 year high of $11.87. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.70 and a quick ratio of 1.41. The firm has a 50-day moving average of $4.63 and a 200 day moving average of $5.05. The company has a market cap of $127.38 million, a P/E ratio of -1.50 and a beta of 1.56.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.